aMoon Fund News
22 articles
משקיעות בביומד: הפרויקטים החדשים של TEAM8 ו-aMOON
Healthcare investment fund aMoon has announced the launch of the second cycle of its Explorer program, designed to invest in academic projects to create the next generation of medical companies in Israel. Pharmaceutical company Merck will join the initiative through its investment arm, Merck Venture. In the first round of aMoon Explorer, aMoon invested in two research projects. Meanwhile, investment group Team8, which has invested in technology companies in the cyber, data and fintech sectors, announced its entry into the digital health sector. The group aims to establish 6-8 companies in the digital health sector over the next five years, with an initial investment of about $10 million per company.
InvestmentPartners
Life sciences VC aMoon raises $340 million for second fund CTech
Israel-based venture capital firm aMoon has raised $340 million for its second fund, aMoon Growth II. The funds Limited Partners include existing investors such as Credit Suisse and new institutional investors like Pictet and a U.S.-based institutional investor. The fund aims to invest in companies at the convergence of technology and biology to improve peoples lives and accelerate medical advancements. The partners in the new fund are Dr. Yair Schindel, Tomer Berkovitz, Todd Sone, and Dr. Gur Roshwalb. aMoons first fund invested in 22 companies, including Genomics and CartiHeal.
Investment
aMoon raising new massive healthtech fund
Israel-based life sciences venture capital firm aMoon is raising a new growth fund. The partners in the new fund include Dr. Yair Schindel, Tomer Berkovitz, Todd Sone, and Dr. Gur Roshwalb. The magnitude of the new fund has not been revealed, but it is expected to be in the region of its previous $750 million fund. Credit Suisse and Marius Nacht were investors in aMoons previous fund.
Investment
"Were concerned at the decline in early-stage startups"
Venture capital fund aMoon has launched a new venture called aMoon Explorer to fund applied science projects in academic institutions. The fund, led by Marius Nacht and Dr. Yair Schindel, plans to invest half a million shekels in each project and has identified three main areas of interest: fibrotic diseases, digital therapeutics, and synthetic biology. aMoon aims to invest in seven initiatives and will issue requests for proposals in other areas every six months. The project is part of aMoons efforts to address the decline in groundbreaking life-science startups and support early-stage projects that have failed to secure funding. The initiative will help establish companies based on the applied science projects and recruit experienced management teams. aMoon is a leading healthcare investment entity in Israel with over $1 billion under management.
InvestmentExpand
aMoon stake in Seer Biotech worth $470m
Israeli health-tech and life sciences venture capital fund aMoon has made impressive returns on its investment in US life sciences company Seer Biotech. aMoon invested several tens of millions of dollars in Seer when it was an early stage startup. Seer held its IPO on Nasdaq and raised $175 million. Since then, the companys share price has risen 242%, giving a market cap of $4.014 billion. aMoons stake in the company is worth $470 million.
InvestmentPublic Trading
"לגעת בחיים של אנשים": קרן אמון ולוסיטי יוצאת לדרך עם גיוס של 100 מיליון דולר
Israeli venture capital fund aMoon, which focuses on various aspects of HealthTech, has completed the raising of a new fund of over $100 million. The new fund, named aMoon Velocity, will invest in early-stage startups in the digital health sector.
Investment
Israel's aMoon fund saw a 15-fold return on its investment in Seer
Israeli venture capital fund aMoon recorded a 15-fold return on investment after its portfolio company Seer Inc. went public on Nasdaq. aMoon invested in Seer in December 2019 when it was valued at $228 million. Seer completed its IPO at a valuation of $1.3 billion and its stock price has nearly tripled since then, reaching a valuation of $3.5 billion. Seer also held a private sale, with Japanese investment giant SoftBank participating, raising a total of $135 million. aMoon kept its 10% stake in the company, now worth $300 million. Seers success is attributed to its family pedigree, with one of its founders being Professor Robert Langer, the scientist behind Modernas mRNA Covid-19 vaccine. Seers breakthrough technology involves protein research and enables the early detection of diseases in blood tests.
Investment
aMoon and Roche to cooperate on digital health
Israeli healthcare venture capital fund aMoon and pharmaceutical giant Roche have launched a joint program for investment in early stage digital health companies. The project is called the Starfinder Digital Innovation Lab. The companies will mark out each year, for the next three years, three subsectors in the field of digital health and will then seek out startups leading in the area. Ultimately they will select nine companies for the venture. In the coming year, aMoon and Roche will seek companies in the fields of lung cancer, resistance to antibiotics, and digital pathology.
Partners
Yair Schindel: aMoon's healthtech anchor
Yair Schindel, the Venture Capital Head of aMoon, a healthtech fund, is working to strengthen the connection between business and medical technologies in Israel. The firm began with a $300 million investment by Marius Nacht, co-founder of Check Point Technologies, and has since raised another $750 million for a second-stage fund and $100 million for an early-stage fund. Schindel is also working on establishing a local branch of the FDA in Israel to improve the process of regulating new products. He is currently assisting the Israeli Health Ministry in combating the Covid-19 pandemic.
Investment
Israel's aMoon leads $110 million funding round in SOPHiA GENETICS
Israel-based life sciences venture capital firm aMoon led a $110 million series F financing round in Swiss Medtech company SOPHiA GENETICS. The funding aims to boost the company’s penetration in both the U.S. and Asian markets. SOPHiA GENETICS operates in the field of medical data and has established the world’s largest data-driven medicine community network based on its universal and collaborative AI platform. The SOPHiA platform is used by over 1,000 healthcare institutions and has analyzed 600,000 genomic profiles.
Investment
Israel's aMoon leads funding rounds in U.S. and European companies
Israeli venture capital fund aMoon has led two funding rounds totaling $65 million for international tech companies. The first round was a $35 million series B funding for MOBILion Systems, a Pennsylvania-based company that develops high-resolution instrumentation for biomarker discovery and diagnostics. The second round was a $30 million financing for MiNA Therapeutics, a UK-based company that develops RNA activation therapeutics for chronic ailments. The funding will be used to advance MiNAs pipeline of proprietary therapeutics and support the clinical development of its cancer treatment. aMoons investments aim to accelerate the development of personalized healthcare and offer breakthroughs in the treatment of cancer and other chronic diseases. The company is proud to be building bridges between foreign companies and Israels healthtech sector.
Investment
https://www.healthcareglobal.com/technology-and-ai-3/roche-invests-millions-israels-health-tech-sector
Roche has entered into a partnership agreement with aMoon, an Israeli venture capital company, to invest in Israeli health tech startups. The collaboration, called the StarFinder Lab, aims to accelerate the development of diagnostic technologies focused on AI-powered solutions and disruptive digital healthcare apps. The partnership will run for three years, with three startups selected each year. Roches Diagnostics division has previously formed partnerships with healthcare companies focusing on AI and data analytics. The digital health sector in Israel is booming, with a significant increase in the number of digital health companies and venture capital funding. The StarFinder Lab program will open for applications in October.
Partners
Roche, aMoon to launch early-stage innovation program
Israel-based life sciences venture capital firm aMoon and Swiss biotechnology company Roche have announced a collaborative agreement to launch an early-stage investment program named StarFinder Digital Innovation Lab. The program will run for the next three years, with three companies selected and receiving investments each year. The program provides elected entrepreneurs access to global expertise, a network of contacts, investment, studies and deep data, and physical office space. The partnership between aMoon and Roche aims to build disruptive startups in the life sciences and healthtech sectors. Roche, a global healthcare company, sees this program as a valuable aspect of their digital healthcare footprint.
InvestmentPartners
aMoon's second healthtech fund tops out at $750 million
Israel-based venture capital firm aMoon has raised an additional $90 million, bringing its second fund to a total of $750 million. The fund, founded by Marius Nacht, focuses on investments in advanced-stage companies in the life sciences sector. Credit Suisse and other major institutional investors in Israel and abroad participated in the funding round. aMoon has already invested $200 million in nine companies and specializes in pharma, digital health, and medical technology. The fund aims to bridge the Israeli healthtech ecosystem with the international market and accelerate innovation in early detection and treatment.
Investment
Nacht's aMoon raising new fund to invest in early stage companies
aMoon Velocity Fund, run by Marius Nacht and Yair Schindels venture capital fund aMoon, has raised over $7 million for investments in early-stage highly disruptive healthcare technologies. The fund has already invested in NanoGhosts, Vocalis Health, and Ibex Medical Analytics. aMoon is one of Israels largest venture capital funds, focusing on digital health, medical equipment, and biopharmaceuticals. The company has previously invested in leading digital health companies in Israel. The reported funding volume is partial, and the actual investment amount is higher but undisclosed due to exchange regulations.
Investment
Healthtech Is Israel's Next Growth Engine, Says Venture Capitalist
Yair Schindel, head of Israeli venture capital fund aMoon, believes that healthcare technologies will put Israel on the global tech map. aMoon, which focuses on life sciences, has $1 billion in assets under management. Schindel believes that the local healthcare sector has the potential to produce at least 10 more mega-companies like Teva Pharmaceutical Industries Ltd. and Check Point Software Technologies Ltd. aMoon has invested around $500 million to date in 31 companies, 20 of them Israel-based and the rest in the U.S.
Investment
Life Sciences Venture Fund aMoon Appoints Fourth Partner
Israel-based venture capital firm aMoon has appointed Tomer Berkovitz as a partner. Berkovitz, who previously served as aMoons managing director and CFO, will lead new investments and strategic collaborations with global finance enterprises. In March, aMoon closed its second fund, aMoon II, at $660 million, making it the largest health tech fund in Israel. The firm was founded in 2016 by Yair Schindel and Marius Nacht and its current portfolio companies include DayTwo, Ibex Medical Analytics, and Zebra Medical Vision.
PartnersInvestment
aMoon closes $660m Israeli health-tech VC fund
Israeli health-tech and life sciences venture capital firm aMoon has closed a $660 million investment fund, making it the largest venture capital fund in Israel and the largest life sciences and healthcare fund ever set up in Israel. The fund has already invested in four Israeli companies and one company in Silicon Valley. The vision of the fund is to invest in relatively advanced stages of companies, filling the gap in financing for important clinical trials and commercialization stages. The fund prefers to lead investment rounds in its portfolio companies. Additionally, aMoon has raised $60 million for another fund named aMoon Velocity, which will invest in breakthrough technologies at the early stages. The investors in the funds include Credit Suisse and Morris Kahn.
Investment
aMoon raises $600m for second life sciences fund - Reuters
Israeli healthcare and life sciences venture capital firm aMoon has received commitments of $600 million from investors and aims to raise up to $750 million for its second fund. The fund will focus on investments in digital health, medical devices, and biopharma in Israel, the US, and Europe. aMoon II had previously received a $250 million investment commitment from Credit Suisse. The fundraising is expected to close in February.
Investment
Life Sciences Venture Fund aMoon Nearing Cap of Second Fund, Says Co-Founder
Israel-based venture capital firm aMoon has exceeded its $500 million target for its second fund and is close to reaching its hard cap of $750 million. The firm, founded in 2016, focuses on mid to late-stage health companies in the domains of pharma, digital health, and medical technology. Credit Suisse AG has committed $250 million to the fund. The fund has secured commitments from over 50 investors and expects to reach between 70 and 80 investors by the time it closes in December.
Investment
Credit Suisse to pump $250 million into Israeli health tech venture fund aMoon
Credit Suisse has formed a strategic partnership with Israeli life-sciences VC fund aMoon, injecting $250 million into aMoons second fund. The partnership will provide exclusive access to aMoons portfolio of companies for Credit Suisses clients and institutional investors outside the US and Canada. aMoon Partners, backed by Israeli billionaire Marius Nacht, recently raised $200 million for its second fund, which focuses on mid- to late-stage life science companies in digital health, medical technologies, and biopharmaceuticals. The new fund aims to integrate digital health advancements into drug and medical device development. Credit Suisse sees health tech as an attractive investment opportunity.
Investment
aMoon raises $200m for second healthtech fund
Israeli healthtech and life sciences venture capital firm aMoon plans to raise a $500 million second fund. The first closing of the fund, at $200 million, will take place in the next few days. The first aMoon fund was set up a year ago, and has so far invested $120 million. aMoon 2 has already started to invest in late-stage companies. Among the companies currently in aMoon 2s portfolio are CartiHeal, Ayala Pharmaceutical, and Biolojic Design.
Investment
